Combination of Vebreltinib and Osimertinib in Patients with EGFR 21 L858R Mutation Advanced NSCLC

Sponsor
National Cancer Center, China
Study ID
NCT06827145
Phase
PHASE2
Status
Active Not Recruiting

Conditions

  • Non-Small-Cell Lung Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Vebreltinib — DRUG
    Vebreltinib 100mg oral BID
  • Osimertinib — DRUG
    Osimertinib 80mg oral once daily.

Study Details

This is a Prospective, open label, single arm study to evaluate the efficacy and safety of Vebreltinib combined with Osimertinib in the treatment of locally advanced or metastatic non-small cell lung cancer with EGFR 21 L858R mutation

Key Dates

Start date
Oct 14, 2024
Status verified
Aug 2024
Primary completion
Sep 30, 2026
Completion
Sep 30, 2028

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Experimental Arm
    All patients received oral Vebreltinib 100mg BID plus Osimertinib 80mg once daily.

Primary Outcome Measure

Progression-free survival [ Time Frame: 3 years ]

Related Studies